ST Yunsheng intends to take control of the acquisition | Three medical device sales companies

On July 4th, ST Yunsheng announced that the company is planning an asset acquisition. The underlying assets to be acquired include but are not limited to: Shaanxi Runze Pharmaceutical Co., Ltd. held by Zhou Yuefeng and Chen Zhengtong 51% of the shares; Zhang Xinping, He Yu and others held the Jiaozuo City Yuntaishan Pharmaceutical Co., Ltd. not less than 51% of the shares; Jiangxi Youth Kangyuan Group Co., Ltd. and Liu Musheng held Jiangxi Youth Kangyuan Pharmaceutical Co., Ltd. Less than 51% of the shares.

According to the announcement, the main business of the above three companies is drug and medical instruments Sales. Among them, Shaanxi Runze medicine The registered capital of the company is 50 million yuan, and the operating income in 2017 is 400 million yuan (unaudited); the registered capital of Jiaozuo Yuntaishan Pharmaceutical Co., Ltd. is 34.03 million yuan, and the operating income in 2017 is 560 million yuan (unaudited); Jiangxi Youth Kangyuan Pharmaceutical Co., Ltd. registered capital of 10 million yuan, 2018 forecast operating income of 400 million yuan.

ST Yunsheng said that the specific transaction method of the acquisition of assets is temporarily uncertain, and there is uncertainty in whether the transaction can be reached. The company will disclose the progress in time according to the actual situation.